227 related articles for article (PubMed ID: 23616122)
21. From the ranks of mammary progesterone mediators, RANKL takes the spotlight.
Fernandez-Valdivia R; Lydon JP
Mol Cell Endocrinol; 2012 Jun; 357(1-2):91-100. PubMed ID: 21964466
[TBL] [Abstract][Full Text] [Related]
22. MPA influences tumor cell proliferation, migration, and invasion induced by RANKL through PRB involving the MAPK pathway in endometrial cancer.
Wang J; Sun X; Zhang H; Wang Y; Li Y
Oncol Rep; 2015 Feb; 33(2):799-809. PubMed ID: 25483570
[TBL] [Abstract][Full Text] [Related]
23. Progestogens and risk of breast cancer: a link between bone and breast?
González Ricarte M; de Castro Pérez A; Tarín JJ; Cano A
Gynecol Endocrinol; 2016; 32(1):6-8. PubMed ID: 26299383
[TBL] [Abstract][Full Text] [Related]
24. RANK expression as a prognostic and predictive marker in breast cancer.
Pfitzner BM; Branstetter D; Loibl S; Denkert C; Lederer B; Schmitt WD; Dombrowski F; Werner M; Rüdiger T; Dougall WC; von Minckwitz G
Breast Cancer Res Treat; 2014 Jun; 145(2):307-15. PubMed ID: 24737168
[TBL] [Abstract][Full Text] [Related]
25. Progesterone receptor integrates the effects of mutated MED12 and altered DNA methylation to stimulate RANKL expression and stem cell proliferation in uterine leiomyoma.
Liu S; Yin P; Kujawa SA; Coon JS; Okeigwe I; Bulun SE
Oncogene; 2019 Apr; 38(15):2722-2735. PubMed ID: 30538295
[TBL] [Abstract][Full Text] [Related]
26. RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy.
Azim HA; Peccatori FA; Brohée S; Branstetter D; Loi S; Viale G; Piccart M; Dougall WC; Pruneri G; Sotiriou C
Breast Cancer Res; 2015 Feb; 17():24. PubMed ID: 25849336
[TBL] [Abstract][Full Text] [Related]
27. RANKL-induced migration of MDA-MB-231 human breast cancer cells via Src and MAPK activation.
Tang ZN; Zhang F; Tang P; Qi XW; Jiang J
Oncol Rep; 2011 Nov; 26(5):1243-50. PubMed ID: 21725611
[TBL] [Abstract][Full Text] [Related]
28. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
[TBL] [Abstract][Full Text] [Related]
29. Progesterone Receptor Signaling Mechanisms.
Grimm SL; Hartig SM; Edwards DP
J Mol Biol; 2016 Sep; 428(19):3831-49. PubMed ID: 27380738
[TBL] [Abstract][Full Text] [Related]
30. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells.
Shin M; Matsuo K; Tada T; Fukushima H; Furuta H; Ozeki S; Kadowaki T; Yamamoto K; Okamoto M; Jimi E
Carcinogenesis; 2011 Nov; 32(11):1634-40. PubMed ID: 21890459
[TBL] [Abstract][Full Text] [Related]
31. High hopes for RANKL: will the mouse model live up to its promise?
Tanos T; Brisken C
Breast Cancer Res; 2011 Jan; 13(1):302. PubMed ID: 21345281
[TBL] [Abstract][Full Text] [Related]
32. Hypoxia induces RANK and RANKL expression by activating HIF-1α in breast cancer cells.
Tang ZN; Zhang F; Tang P; Qi XW; Jiang J
Biochem Biophys Res Commun; 2011 May; 408(3):411-6. PubMed ID: 21514280
[TBL] [Abstract][Full Text] [Related]
33. RANKL promotes the growth of decidual stromal cells in an autocrine manner via CCL2/CCR2 interaction in human early pregnancy.
Meng YH; Li H; Chen X; Liu LB; Shao J; Chang KK; Du MR; Jin LP; Li MQ; Li DJ
Placenta; 2013 Aug; 34(8):663-71. PubMed ID: 23697850
[TBL] [Abstract][Full Text] [Related]
34. RANKL/RANK: from bone loss to the prevention of breast cancer.
Sigl V; Jones LP; Penninger JM
Open Biol; 2016 Nov; 6(11):. PubMed ID: 27881737
[TBL] [Abstract][Full Text] [Related]
35. Paracrine-rescued lobulogenesis in chimeric outgrowths comprising progesterone-receptor-null mammary epithelium and redirected wild-type testicular cells.
Bruno RD; Boulanger CA; Rosenfield SM; Anderson LH; Lydon JP; Smith GH
J Cell Sci; 2014 Jan; 127(Pt 1):27-32. PubMed ID: 24190884
[TBL] [Abstract][Full Text] [Related]
36. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
[TBL] [Abstract][Full Text] [Related]
37. Reduction of human metastatic breast cancer cell aggressiveness on introduction of either form a or B of the progesterone receptor and then treatment with progestins.
Sumida T; Itahana Y; Hamakawa H; Desprez PY
Cancer Res; 2004 Nov; 64(21):7886-92. PubMed ID: 15520195
[TBL] [Abstract][Full Text] [Related]
38. Receptor activator for NF-κB ligand in acute myeloid leukemia: expression, function, and modulation of NK cell immunosurveillance.
Schmiedel BJ; Nuebling T; Steinbacher J; Malinovska A; Wende CM; Azuma M; Schneider P; Grosse-Hovest L; Salih HR
J Immunol; 2013 Jan; 190(2):821-31. PubMed ID: 23241893
[TBL] [Abstract][Full Text] [Related]
39. Expression of RANK-ligand in prostate cancer cell lines.
Penno H; Nilsson O; Brändström H; Winqvist O; Ljunggren O
Scand J Clin Lab Invest; 2009; 69(1):151-5. PubMed ID: 19058084
[TBL] [Abstract][Full Text] [Related]
40. Targeting RANKL in breast cancer: bone metastasis and beyond.
Azim H; Azim HA
Expert Rev Anticancer Ther; 2013 Feb; 13(2):195-201. PubMed ID: 23406560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
